Clinical Trial Update: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MS-275 (entinostat) in patients with advanced solid tumors or lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma

Drugs mentioned

• MS-275 (entinostat)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Cancer | Phase 1 | Status: COMPLETED